Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaap Verweij

Showing results (41-50 of 234) with videos related to

Pageof 24
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 14, 2006
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a reviewFerry A L M Eskens, Jaap Verweij
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
The multi-institutional phase I study: disadvantages without advantages?Jaap Verweij, Ferry Eskens, Maja de Jonge
Seminars in Oncology|February 14, 2006
Renal toxicities of chemotherapyMaja J A de Jonge, Jaap Verweij
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Phase I studies of drug combinationsJaap Verweij, Mary L Disis, Stephen A Cannistra
Pharmaceutical Statistics|April 10, 2014
A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugsDavid Dejardin, Emmanuel Lesaffre, Paul Hamberg, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2006
"The Art of Successful Publication" ECCO 13 workshop reportJohn Smyth, Jaap Verweij, Maurizio D'Incalci, et al.
Clinical Colorectal Cancer|November 15, 2006
Practical aspects of managing gastrointestinal stromal tumorsStefan Sleijfer, Caroline Seynaeve, Erik Wiemer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Precision oncology: an overviewLevi A Garraway, Jaap Verweij, Karla V Ballman
The Oncologist|July 3, 2007
Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatmentStefan Sleijfer, Erik Wiemer, Caroline Seynaeve, et al.
Nature Reviews. Clinical Oncology|March 26, 2014
Determining the optimal dose in the development of anticancer agentsRon H J Mathijssen, Alex Sparreboom, Jaap Verweij
Pageof 24

Showing results (41-50 of 234) with videos related to

Sort By:
Pageof 24
European Journal of Cancer (Oxford, England : 1990)|November 14, 2006
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a reviewFerry A L M Eskens, Jaap Verweij
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
The multi-institutional phase I study: disadvantages without advantages?Jaap Verweij, Ferry Eskens, Maja de Jonge
Seminars in Oncology|February 14, 2006
Renal toxicities of chemotherapyMaja J A de Jonge, Jaap Verweij
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2010
Phase I studies of drug combinationsJaap Verweij, Mary L Disis, Stephen A Cannistra
Pharmaceutical Statistics|April 10, 2014
A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugsDavid Dejardin, Emmanuel Lesaffre, Paul Hamberg, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2006
"The Art of Successful Publication" ECCO 13 workshop reportJohn Smyth, Jaap Verweij, Maurizio D'Incalci, et al.
Clinical Colorectal Cancer|November 15, 2006
Practical aspects of managing gastrointestinal stromal tumorsStefan Sleijfer, Caroline Seynaeve, Erik Wiemer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Precision oncology: an overviewLevi A Garraway, Jaap Verweij, Karla V Ballman
The Oncologist|July 3, 2007
Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatmentStefan Sleijfer, Erik Wiemer, Caroline Seynaeve, et al.
Nature Reviews. Clinical Oncology|March 26, 2014
Determining the optimal dose in the development of anticancer agentsRon H J Mathijssen, Alex Sparreboom, Jaap Verweij
Pageof 24